NuCana Q2 EPS £(0.12) Vs £(0.10) YoY
NuCana Q2 EPS £(0.12) Vs £(0.10) YoY
Key Data Readouts on Track for All Programs in 2024
2024 年所有項目的關鍵數據均有望公佈
Anticipated Cash Runway into Q1 2025
預計現金流將持續到2025年第一季度
EDINBURGH, United Kingdom, Aug. 15, 2024 (GLOBE NEWSWIRE) -- NuCana plc (NASDAQ:NCNA) announced financial results for the second quarter ended June 30, 2024 and provided an update on its broad clinical development program with its transformative ProTide therapeutics.
英國愛丁堡，2024年8月15日（GLOBE NEWSWIRE）——NuCana plc（納斯達克股票代碼：NCNA）公佈了截至2024年6月30日的第二季度財務業績，並提供了其變革性ProTide療法的廣泛臨床開發計劃的最新情況。
As of June 30, 2024, NuCana had cash and cash equivalents of £11.6 million compared to £12.9 million as of March 31, 2024 and £17.2 million at December 31, 2023. NuCana continues to advance its numerous clinical programs and reported a net loss of £7.0 million for the quarter ended June 30, 2024, as compared to a net loss of £5.4 million for the quarter ended June 30, 2023. Basic and diluted loss per ordinary share was £0.12 for the quarter ended June 30, 2024, as compared to £0.10 per ordinary share for the comparable quarter ended June 30, 2023.
截至2024年6月30日，NuCana的現金及現金等價物爲1160萬英鎊，而截至2024年3月31日爲12.9萬英鎊，截至2023年12月31日爲17.2萬英鎊。NuCana繼續推進其衆多臨床項目，並報告稱，截至2024年6月30日的季度淨虧損爲700萬英鎊，而截至2023年6月30日的季度淨虧損爲54萬英鎊。截至2024年6月30日的季度，普通股每股基本虧損和攤薄虧損爲0.12英鎊，而截至2023年6月30日的同期每股普通股虧損爲0.10英鎊。